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Objective: Pathological changes within the hypothalamus have been proposed to mediate circadian rhythm and
habitual sleep disturbances in individuals with Huntington’s disease (HD). However, investigations examining
the relationships between hypothalamic volume and circadian rhythm and habitual sleep in individuals with HD
are sparse. This study aimed to comprehensively evaluate the relationships between hypothalamic pathology
and circadian rhythm and habitual sleep disturbances in individuals with premanifest HD.
Methods: Thirty-two individuals with premanifest HD and twenty-nine healthy age- and gender-matched controls participated in this dual-site, cross-sectional study. Magnetic resonance imaging scans were performed to
evaluate hypothalamic volume. Circadian rhythm and habitual sleep were assessed via measurement of morning
and evening cortisol and melatonin levels, wrist-worn actigraphy, the Consensus Sleep Diary and sleep questionnaires. Information on mood, physical activity levels and body composition were also collected.
Results: Compared to healthy controls, individuals with premanifest HD displayed signiﬁcantly reduced grey
matter volume in the hypothalamus, decreased habitual sleep eﬃciency and increased awakenings; however, no
alterations in morning cortisol or evening melatonin release were noted in individuals with premanifest HD.
While diﬀerences in the associations between hypothalamic volume and cortisol and melatonin output existed in
individuals with premanifest HD compared to healthy controls, no consistent associations were observed between hypothalamic volume and circadian rhythm or habitual sleep outcomes.
Conclusion: While signiﬁcant diﬀerences in associations between hypothalamic volume and cortisol and melatonin existed between individuals with premanifest HD and healthy controls, no diﬀerences in circadian markers
were observed between the groups. This suggests that circadian regulation is maintained despite hypothalamic
pathology, perhaps via neural compensation. Longitudinal studies are required to further understand the relationships between the hypothalamus and circadian rhythm and habitual sleep disturbances in HD as the
disease course lengthens.
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1. Introduction

All aspects of the study were conducted in accordance with the
Declaration of Helsinki. Ethical approval was granted by the Edith
Cowan University and Monash University Human Research Ethics
Committees. All participants provided written informed consent.

Circadian rhythm and habitual sleep disturbances are common
features of Huntington’s disease (HD) that occur early in the disease
course and exacerbate impairments in cognitive function, metabolism,
hormone regulation, mood and quality of life (Aziz et al., 2010;
Briançon-Marjollet et al., 2015; Lazar et al., 2015; Morton et al., 2005).
A number of studies have reported dysregulation of markers of
circadian rhythm and habitual sleep-wake outcomes in individuals with
HD. In particular, increased morning cortisol output has been reported
in individuals with premanifest HD (Hubers et al., 2015; van Duijn
et al., 2010). Reduced mean and acrophase concentrations and a temporal spread of melatonin release, indicating a potential phase shift in
melatonin, have been reported in individuals with premanifest HD
(Kalliolia et al., 2014). Furthermore, studies have reported disruption of
the sleep-wake cycle and delayed sleep phase in individuals with HD
(Aziz et al., 2010; Morton et al., 2005). Despite these ﬁndings, the
neurobiological origin of circadian rhythm and habitual sleep-wake
disturbances in individuals with HD has been poorly investigated and
warrants further exploration.
Pathological changes within the hypothalamus have been proposed
to disrupt circadian rhythm and sleep in individuals with HD (Aziz
et al., 2010; Morton et al., 2005). Hypothalamic nuclei, particularly the
suprachiasmatic nucleus, are known to be integrally involved in the
regulation of circadian markers such cortisol and melatonin, as well as
sleep (Saper et al., 2005; Steiger, 2002). Studies have reported grey
matter volume loss and microglial activation within the hypothalamus
and circadian rhythm and sleep disturbances that arise concomitantly
in individuals with premanifest HD (Lazar et al., 2015; Morton et al.,
2005; Politis et al., 2008; Soneson et al., 2010). Despite these ﬁndings,
only one study has examined the potential link between neural pathology and circadian rhythm and sleep disturbances in individuals
with HD (Baker et al., 2016). Baker et al. (2016) reported an association
between subjective sleep disturbances and neural pathology in HD.
However, the authors did not use formalised sleep questionnaires to
examine sleep and did not evaluate markers of circadian rhythm relative to neural pathology. There is, therefore, a need for subsequent
research to investigate more closely the potential relationships between
hypothalamic pathology and circadian rhythm and sleep disturbances
in HD.
The purpose of this study was to evaluate whether hypothalamic
pathology is associated with the dysregulation of biological and clinical
markers of circadian rhythm, particularly cortisol, melatonin and sleepwake timing, and habitual sleep in individuals with premanifest HD. We
hypothesized that hypothalamic pathology would be associated with
dysregulation of circadian rhythm and habitual sleep, as evidenced by
signiﬁcant alterations in cortisol and melatonin release and habitual
sleep-wake cycles in individuals with premanifest HD.

2.2. Study procedures
Testing procedures included 3T MRI scans for hypothalamic imaging, saliva sampling to quantify morning cortisol and evening melatonin, wrist-worn actigraphy for monitoring sleep, a sleep diary for
monitoring habitual sleep patterns and questionnaires for monitoring
sleep quality, psychological stress, physical activity, anxiety and depression.
2.3. Acquisition and pre-processing of MRI data
T1-weighted structural images of the brain were obtained from each
participant in Perth or Melbourne using a GE Healthcare Discovery and
a Siemens Skyra 3T MRI scanner, respectively. In Perth, images were
acquired with a 24-channel head coil using an IR-SPGR sequence (TA =
9 m 59 s, TR = 3 s, TE = Min, TI = 400 ms, ﬂip angle = 11°, ﬁeld of
view = 256 mm, image matrix = 256 × 256, 1 mm3 isotropic voxels).
In Melbourne, acquisition took place with a 32-channel head coil and
an MP-RAGE sequence (TA = 9 m 14 s, TR = 2.3 s, TE = 2.96 ms, TI =
900 ms, ﬂip angle = 9°, ﬁeld of view = 256 mm, image matrix = 256
× 256). Images were acquired consistently across both sites according
to the Alzheimer’s Disease Neuroimaging Initiative protocols for multisite imaging (Jack et al., 2008). Pre-processing of images was conducted according to the SPM12 pipeline (Supplementary data).
2.4. Measurement of biological markers of circadian rhythm
Salivary cortisol and melatonin have previously been shown to be
useful measures of circadian rhythm (Dickmeis, 2009; Voultsios et al.,
1997). Participants were given written and verbal instructions to collect
saliva samples by passive drool into polypropylene collection tubes (SSI
Bio) at the same time on two consecutive days for determination of
morning cortisol and evening melatonin concentrations. Participants
collected saliva samples at four time points in the morning (15, 30, 45
and 60 min following awakening) for morning cortisol analysis and four
time points in the evening at one hour intervals from two hours before
their usual bedtime (T1) until one hour after their usual bedtime (T4)
for melatonin analysis. Saliva samples were collected according to criteria from previous studies (van Duijn et al., 2010; Voultsios et al.,
1997) to avoid contamination of samples (see Supplementary ﬁles).
Based on these criteria, a questionnaire was devised to monitor participant compliance. Saliva samples were stored at −80 °C until analysis
using commercially available salivary cortisol and melatonin ELISA kits
(Salimetrics, USA) according to the manufacturer’s instructions.

2. Materials and methods
2.5. Measures of habitual sleep-wake parameters
2.1. Participants
2.5.1. Actigraphy
At the commencement of the study, a convenience sample of individuals with premanifest HD and healthy controls were given the
opportunity to undertake habitual sleep monitoring using actigraphy.
Of the original cohort, 19 premanifest HD and 24 healthy individuals
underwent home-based actigraphy sleep measurement for seven consecutive nights to assess habitual sleep-wake patterns. Actigraphy was
recorded at 30 Hz using wrist-worn GT3X+ ActiGraph monitors
(ActiGraph, USA) on the non-dominant wrist. The start and end time of
sleep periods were recorded using the Consensus Sleep Diary (Carney
et al., 2012).
Wrist-based actigraphy has been used previously to assess circadian
rhythm via analysis of habitual sleep-wake patterns in individuals with
HD and in other populations (Ancoli-Israel et al., 2003; Morton et al.,

Thirty-ﬁve premanifest HD individuals and 31 age- and gendermatched healthy controls were recruited from existing databases, HD
clinics and media advertisements in Perth and Melbourne. Inclusion
criteria for premanifest HD individuals were a cytosine-adenine-guanine (CAG) repeat length ≥ 40 and a diagnostic conﬁdence score < 2
on the Uniﬁed Huntington’s Disease Rating Scale Total Motor Score
(UHDRS-TMS) (Reilmann et al., 2014). Exclusion criteria for all participants were, presence of known musculoskeletal, metabolic, endocrine, cardiovascular or sleep disorders, recent or long-standing substance abuse, shift work other neurological conditions and, for healthy
controls, a family history of HD. Five participants withdrew from the
study or contributed incomplete data and were excluded from analyses,
leading to a total of 32 premanifest HD and 29 healthy individuals.
2
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2005). Therefore, here we similarly used ActiGraph monitors, which
were initialised, downloaded and analysed using the ActiLife software
(version 6.8). Data were scored with a low frequency extension ﬁlter in
60 s epochs as awake or sleep according to the Cole-Kripke algorithm
(Cole et al., 1992). Total sleep time, sleep onset latency, wake after
sleep onset, number of awakenings and sleep eﬃciency outcomes were
calculated for each night and then averaged across the seven nights to
obtain single values for use in subsequent analyses.

2.8.2. Salivary cortisol and melatonin
Missing data points from saliva sampling (removed due to suspected
blood contamination) were imputed by calculating the average of the
participant’s previous and subsequent values in the curve (n= 2 of 504,
0.40%), unless the missing value was the ﬁrst time point in each curve
(n= 3 of 504, 0.60%), in which case the group average was imputed to
avoid removing the participant from analyses and maintain sample size
(van Duijn et al., 2010). Area under the curve with respect to ground
(AUCG) was calculated using the trapezoid rule for morning cortisol and
evening melatonin output on the two consecutive days (Dijk et al.,
2012; van Duijn et al., 2010).
Normality assumptions for all variables were tested using a ShapiroWilk test. Between-group diﬀerences were examined using a t-test for
continuous variables and a two sample proportion test for categorical
variables. Spearman correlation coeﬃcient was calculated to assess
relationships between cortisol AUCG, melatonin AUCG and Perceived
Stress Scale, PSQI and Consensus Sleep Diary scores. Statistical signiﬁcance was set at p ≤ 0.05. Statistical analyses were performed using
STATA version 9.1.

2.5.2. Consensus sleep diary
Habitual sleep-wake timing was evaluated using the Consensus
Sleep Diary (Carney et al., 2012). Participants were required to document time in bed, time of awakening, time to sleep onset, number of
awakenings and sleep quality for seven nights in combination with
actigraphy assessment.
2.5.3. Subjective sleep quality and daytime somnolence
Sleep quality was assessed in all participants using the Pittsburgh
Sleep Quality Index (PSQI) (Buysse et al., 1989). Daytime somnolence
was measured using the Epworth Sleepiness Scale (ESS) (Johns, 1991).

3. Results
2.6. Stress, anxiety and depression symptomatology
3.1. Participant demographics and clinical characteristics
The Perceived Stress Scale (Cohen et al., 1983) was used to measure
psychological stress in the previous month. The Perceived Stress Scale
has been demonstrated to be a valid measure of perceived psychological
stress in individuals with HD (Downing et al., 2011). Symptoms of
anxiety and depression were measured using the Hospital Anxiety and
Depression Scale (HADS). This scale has been previously demonstrated
to be valid and reliable in HD (De Souza et al., 2010).

There were no signiﬁcant diﬀerences for age or gender between
premanifest HD patients and healthy controls (p = 0.472 and 0.283,
respectively; Table 1).
Table 1
Demographic and clinical characteristics of premanifest Huntington's disease
and healthy control participants.
Healthy
Controls
(n=29)

p-value

44.3 ± 10.8
8 (27.6)

0.472
0.283

42.8 ± 2.8
47.4 (44.9–55.7)

N/A
N/A

N/A
N/A

0.38 ± 0.70

N/A

N/A

4.35 ± 7.24
305.0 ± 76.8

N/A
N/A

N/A
N/A

0.89 ± 0.18
26.47 ± 4.5
6 (18.8)
5 (15.6)

N/A
26.75 ± 5.9
0 (0.0)
6 (20.7)

N/A
0.417
0.007*
0.303

3 (9.4)

5 (17.2)

0.181

3278.0 ± 6272.5
168 ± 359.2

7481.2 ± 9584.5
85.1 ± 211.8

0.022*
0.141

Premanifest HD
(n=32)

2.7. Physical activity
Physical activity levels were recorded prior to and during saliva
sampling days using the Minnesota Leisure Time Physical Activity
Questionnaire. Metabolic equivalents (METs) were calculated using
recorded physical activity levels, the Compendium of Physical
Activities database and estimated resting metabolic rate (RMR)
(Ainsworth et al., 2011). RMR was calculated using the Harris-Benedict
formula (see Supplementary ﬁle) (Harris and Benedict, 1918).

Demographic Characteristics
Age, mean ± SD
44.5 ± 11.4
Male, n (%)
11 (34.4)
Clinical Characteristics
CAGn, mean ± SD
Estimated age of onset,
median (IQR)
Diagnostic Conﬁdence
Level, mean ± SD
UHDRS-TMS, mean ± SD
Disease burden score, mean
± SD
CAPs, mean ± SD
BMI, mean ± SD
Smoker, n (%)
High alcohol consumption,
n (%)**
Psychotropic medication, n
(%)
Monthly METs, mean ± SD
METs (previous day), mean
± SD

2.8. Statistical analysis
2.8.1. Hypothalamic volume
A hypothalamus mask from the WFU Pick Atlas (http://fmri.wfubmc.edu/software/pickatlas), dilated by 3 mm, was used to restrict
analysis to this area (Breen et al., 2016). Grey matter images from individuals with premanifest HD and healthy controls were compared
voxel-wise using a two-sample t-test to evaluate group diﬀerences in the
hypothalamus. Gender, site and age were included as covariates of no
interest. Next, we investigated group diﬀerences in the association between hypothalamic volume and cortisol and/or melatonin output in
individuals with premanifest HD compared to healthy controls, using a
categorical by continuous covariate interaction model. The model included group regressors, one for each group, and regressors modelling
change in cortisol or melatonin output, one for each group. The following contrasts were used to model the group by cortisol/melatonin
output interaction eﬀect: [0 0 1 −1] and [0 0 −1 1]. Gender, site, age,
PSS, ESS, and PSQI were included as covariates of no interest. In premanifest HD, we adjusted also for CAP score.
We also evaluated the relationship between hypothalamic volume
and disease status (i.e. CAP score). Given the exploratory nature of this
study and our a priori interest in the hypothalamus, the threshold for
statistical signiﬁcance for all analyses was set at α = 0.05.

Group diﬀerences were analysed using t-tests for continuous variables and two
sample proportion tests for categorical variables. Disease burden score was
calculated using the formula: age x (CAGn – 35.5). CAPs was calculated using
the formula: (age x (CAGn - 33.66))/432.3326.
HD = Huntington's disease; CAGn = number of cytosine-adenine-guanine repeats; UHDRS-TMS = Uniﬁed Huntington's Disease Rating Scale-Total Motor
Score; CAPs = scaled CAG age product score; BMI = body mass index; MET=
metabolic equivalents; METs (previous day) refers to the METs calculated for
the day prior to saliva sampling; N/A = not applicable.
* Results are signiﬁcant at p < 0.05
** High alcohol consumption equates to in excess of 14 alcoholic drinks per
week
3
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Fig. 1. Results from voxel-based morphometry analyses showing overlap between maps of (A) the hypothalamic volume group diﬀerence, (B) association between
hypothalamus loss and CAPs in premanifest HD, (C) group by cortisol output interaction and (D) group by melatonin output interaction. (E) shows the map of group
by cortisol output interaction eﬀect on hypothalamic volume (as per voxel-wise analysis) and a scatterplot illustrating the interaction and (F) shows the map of group
by melatonin output interaction eﬀect on hypothalamic grey matter volume and scatterplot illustrating the interaction. The data points in the scatterplot correspond
to the average intensity across all voxels within the area exhibiting a signiﬁcant interaction eﬀect for each participant. Slice labels are displayed on top. Cross-slices
are shown. Crosshairs in (A), (B), (C), and (D) are centred at MNI -9 1 -5. L= left; R= right.

4
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signiﬁcant negative association in premanifest HD between grey matter
volume bilaterally in the anterior-superior and anterior-inferior regions
of the hypothalamus and CAP score (r = -0.42; see Table 3 and Fig. 1B).

Table 2
Cortisol and melatonin values, subjective and objective sleep outcomes and
stress, anxiety and depression questionnaire scores for premanifest Huntington's
disease and healthy control participants.
Premanifest HD

Healthy
Controls

Cortisol nmol/L (mean ± SD)
Time of awakening (hh:mm)

6:06 ± 1:01

6:21 ± 0:45

0.141

Time of sample relative to
awakening:
+15 min
+30 min
+45 min
+60 min
AUCG

11.08 ± 4.40
13.84 ± 4.59
13.69 ± 3.56
12.26 ± 3.47
38.17 ± 11.30

11.28 ± 3.32
13.42 ± 4.29
13.30 ± 4.41
11.62 ± 3.72
39.20 ± 10.61

0.421
0.357
0.352
0.244
0.357

Melatonin (pg/mL)
Reported usual bedtime (hh:mm)

22:05 ± 0:50

22:10 ± 0:31

0.322

Time of sample relative to
bedtime:
-2 h
-1 h
+0 h
+1 h
AUCG

10.87 ± 7.68
12.16 ± 7.07
17.10 ± 9.30
19.42 ± 12.02
49.20 ± 25.88

10.02 ± 6.19
13.71 ± 7.84
19.44 ± 11.10
22.07 ± 11.11
44.41 ± 21.77

0.319
0.210
0.187
0.188
0.219

464.28 ± 46.73
403.17 ± 45.20
7.10 ± 6.80
54.02 ± 25.97
18.47 ± 6.72
2.87 ± 0.64

458.58 ± 43.10
415.12 ± 40.25
4.39 ± 3.77
39.07 ± 16.87
14.55 ± 5.33
2.75 ± 0.87

0.680
0.365
0.106
0.028*
0.039*
0.625

86.98 ± 5.42
5.76 ± 3.02
4.69 ± 3.61

90.68 ± 3.75
4.97 ± 2.44
6.76 ± 3.37

0.012*
0.134
0.025*

430.42 ± 61.33
385.82 ± 53.90
16.65 ± 19.90
19.04 ± 25.37
90.52 ± 5.17
1.25 ± 1.47
10.18 ± 23.46

434.84 ± 68.48
387.92 ± 74.77
14.35 ± 13.92
16.93 ± 22.89
89.32 ± 9.96
1.75 ± 1.03
8.97 ± 11.11

0.372
0.453
0.303
0.412
0.487
0.057
0.059

3.75 ± 0.81
17.12 ± 6.72

3.80 ± 0.92
19.86 ± 6.85

0.411
0.062

7.54 ± 5.30
5.06 ± 3.48
2.49 ± 2.52

8.38 ± 5.69
6.00 ± 3.97
2.38 ± 2.14

0.276
0.164
0.427

Actigraphy measures:
Total time in bed (min)
Total sleep time (min)
Sleep onset latency (min)
Wake after sleep onset (min)
Number of awakenings
Average duration of awakenings
(min)
Sleep eﬃciency (%)
PSQI global score
Epworth Sleepiness Scale Score
Consensus Sleep Diary:
Total time in bed (min)
Total sleep time (min)
Sleep onset latency (min)
Wake after sleep onset (min)
Sleep eﬃciency
Number of awakenings
Average duration of awakenings
(min)
Restorative quality of sleep
Perceived Stress Scale
HADS:
Total score
Anxiety
Depression

3.3. Biological markers of circadian rhythm

p-value

No signiﬁcant diﬀerences were observed between individuals with
premanifest HD and healthy control participants in the amplitude of
morning cortisol or evening melatonin output at any of the time points
sampled (p > 0.05; Table 2). Furthermore, no diﬀerences were observed in total morning cortisol (p = 0.357) or evening melatonin (p =
0.219) output when subject to area under the curve analysis with respect to ground (AUCG; Table 2).
3.4. Habitual sleep outcomes
3.4.1. Actigraphy
Premanifest HD individuals exhibited a decreased sleep eﬃciency
compared to healthy controls (p = 0.012). A signiﬁcant increase in the
number of awakenings (p = 0.039) and time spent awake after sleep
onset (p = 0.028) were also observed in premanifest HD participants
compared to healthy controls (Table 2).
3.4.2. Consensus sleep diary
No signiﬁcant diﬀerences were observed in self-report sleep outcomes using the Consensus Sleep Diary (Table 2).
3.4.3. Subjective sleep outcomes
There were no signiﬁcant diﬀerences between premanifest HD individuals and healthy controls in global PSQI score (p = 0.134). The
average PSQI score in the premanifest HD group fell above the cut-oﬀ of
5, suggesting a disruption in sleep quality. Although healthy controls
scored signiﬁcantly higher than premanifest HD individuals on the ESS,
scores for both groups remained within the normative range (< 10)
(Johns, 1991).
3.5. Stress, anxiety and depression questionnaires
No signiﬁcant diﬀerences were observed in stress (p = 0.062), anxiety (p = 0.164) or depression (p = 0.427) symptomatology between
premanifest HD and healthy individuals (Table 2). Furthermore, values
on the Perceived Stress Scale and HADS were considered below
threshold, indicating no clinically meaningful stress, anxiety or depressive symptomatology in the premanifest HD and healthy control
groups.

Data are reported as mean and standard deviation, unless stated otherwise.
Group diﬀerences were analysed using t-tests. AUCG was calculated using the
trapezoid rule for morning cortisol and evening melatonin output using the
curve generated from the average cortisol values and the average melatonin
values, respectively. Sleep eﬃciency was calculated using the formula: (total
sleep time/total time in bed) X 100. PSQI score greater than 5 indicates poor
sleepers. The Consensus Sleep Diary- restorative quality of sleep item is a Likert
scale ranging from 1 (not restorative) to 5 (very restorative). Higher Perceived
Stress Scale scores indicate greater stress. HADS sub-scores greater than 7 indicate clinically relevant anxiety and depression symptomatology.
HD= Huntington's disease; AUCG= area under the curve with respect to
ground; PSQI= Pittsburgh Sleep Quality Index; HADS= Hospital Anxiety and
Depression Scale.
* Results are signiﬁcant at p < 0.05.

3.6. Physical activity
The premanifest HD group reported signiﬁcantly less monthly
physical activity (METs) than healthy controls (p = 0.022; Table 1).
Physical activity on the day prior to saliva sampling did not diﬀer between the groups, negating any acute eﬀects of physical activity on
hormone levels. Furthermore, there was no association between reported physical activity levels and measures of sleep, cortisol and
melatonin output and hypothalamic volume.
3.7. Associations between hypothalamic volume and circadian markers
A signiﬁcant negative association was revealed by voxel-wise analysis between grey matter volume in the left hypothalamus and morning
cortisol output in the premanifest HD group. This association was found
to be moderate (r = -0.39), indicating that lesser grey matter volume in
the left side of the hypothalamus is associated with greater morning
cortisol output. No signiﬁcant association was observed in the healthy
control group (Fig. 1E and Table 3). This group diﬀerence in the association between hypothalamic volume and morning cortisol output

3.2. Hypothalamic volume
A signiﬁcant decrease in grey matter volume in the anterior-superior region of the left side of the hypothalamus was observed in individuals with premanifest HD compared to healthy controls (peak
voxel at MNI -9 1 -4; t = 2.38; k = 22; see Fig. 1A). We also found a
5
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visible anatomic landmarks in MR images (Makris et al., 2013), this
reduced grey matter volume can be located to the anterior-superior
region of the hypothalamus, a region comprising the paraventricular
nucleus (PVN), which mediates the release of cortisol and melatonin.
Reduced hypothalamic volume was found to be associated with CAP
score, suggesting a relationship between estimated time to disease onset
and loss of hypothalamic grey matter volume. Interestingly, degeneration within the hypothalamus was leftward biased. The reason for this is
unknown. Studies have reported a leftward-biased pattern of grey
matter atrophy in the striatum in individuals with manifest HD
(Minkova et al., 2018; Mühlau et al., 2007), however, this has not been
reported in the striatum or the hypothalamus in individuals with premanifest HD. Minkova et al. (2018) postulated that the earliest pathological changes in the hypothalamus occur on the left side and become
more apparent as individuals approach clinical onset, however additional research is needed to support this supposition.
The pathological mechanisms responsible for reduced hypothalamic
volume in individuals with HD are not yet understood. Evidence from
post-mortem investigations and studies in mouse models provides insight into potential mechanisms by which hypothalamic changes could
occur, as well as mechanisms by which these changes could impact on
circadian rhythm and habitual sleep outcomes. For example, neuronal
inclusions of mutant huntingtin in suprachiasmatic nucleus (SCN) tissue
at post-mortem (Aziz et al., 2008), may directly mediate changes in the
functioning of the SCN. Such neuronal inclusions of mutant huntingtin
within the SCN could reduce the number of vasoactive intestinal
polypeptide and arginine vasopressin expressing neurons, which are
crucial in the regulation of SCN activity (Aton et al., 2005; Hofman and
Swaab, 1994), as well as post-transcriptional changes in these neuropeptides, which have been reported in HD (van Wamelen et al., 2013).
These changes, together with a loss of orexin-releasing neurons in the
lateral hypothalamus which has been reported in individuals with HD
at post-mortem and in mouse models of HD (Aziz et al., 2008; Petersén
et al., 2005), could result in impaired functioning of the hypothalamic
nuclei and lead to the disruption of the circadian rhythm and sleepwake cycle that has been reported in individuals with HD and in HD
mouse models (Kudo et al., 2011; Loh et al., 2013; Morton, 2013;
Morton et al., 2005). These potential mechanisms are complex and
interrelated and require further investigation.
The reduction in hypothalamic grey matter volume in individuals
with premanifest HD was signiﬁcantly associated with morning cortisol
release. This relationship was not observed in healthy controls.
Conversely, the association between hypothalamic volume and evening
melatonin concentrations observed in healthy controls was absent in
individuals with premanifest HD. Both the group by cortisol output and
the group by melatonin output interaction eﬀect on hypothalamic grey
matter volume occurred across regions encompassing the SCN and the
PVN. Despite signiﬁcantly reduced habitual sleep eﬃciency and an
increase in the number of awakenings and time spent awake after sleep
onset in individuals with premanifest HD, which aligns with previous
reports of sleep disturbances in premanifest HD (Lazar et al., 2015),
hypothalamic volume was not signiﬁcantly associated with habitual
sleep outcomes. The lack of consistent associations between hypothalamic volume and habitual sleep outcomes was unexpected, especially
considering the known role of the hypothalamus in regulating the sleepwake cycle via the SCN and its connections with the ventrolateral
preoptic nucleus and the lateral area within the hypothalamus (Bartlett
et al., 2016; Saper et al., 2005).
While inconsistent relationships were observed between hypothalamic volume and habitual sleep outcomes, further studies should assess
the impact of reduced hypothalamic volume on changes in the underlying sleep electroencephalogram, which is reported to be altered in HD
mouse models and in individuals with HD (Fisher et al., 2013; Fisher
et al., 2016; Kantor et al., 2013; Lazar et al., 2015; Piano et al., 2017).
Such analyses would allow further characterisation of the impact of
hypothalamic changes on sleep outcomes in HD.

Table 3
Association analyses between hypothalamic volume and CAPs, cortisol and
melatonin.
Side

CAPs
Negative association with CAPs in
premanifest HD
Cortisol
Negative association with cortisol
output in premanifest HD
Group by cortisol output interaction
Melatonin
Positive association with melatonin
output in healthy controls
Group by melatonin output interaction

k

Peak voxel
t score

MNI coordinates

B

204

3.16

-3 2 -7

L

161

2.54

-10 1 -4

L

186

2.32

-10 1 -4

L

161

2.67

-10 1 -6

L

201

2.41

-6 2 -8

Group diﬀerences were analysed using two-sample t-tests.
*Results are signiﬁcant at p < 0.05, uncorrected.
k = No. of voxels; MNI = Montreal Neurological Institute; HD = Huntington's
disease; B = bilateral; L = left.

was statistically signiﬁcant, as shown by interaction analysis (Fig. 1C,
Fig. 1E and Table 3). The group by cortisol output interaction encompassed two separate areas – ﬁrst, the region spanning the posterior
hypothalamus and the superior tuberal hypothalamus and second, the
anterior-inferior hypothalamic region.
A negative relationship between grey matter volume in the right
side of the hypothalamus and morning cortisol output was seen in
healthy controls, but not in premanifest HD participants, and the group
by cortisol output interaction was signiﬁcant (Table 3). However, the
association between right hypothalamic grey matter volume and
morning cortisol output in healthy controls was weak (r = -0.06), indicating a non-existent relationship in this case.
Grey matter volume in the left side of the hypothalamus was positively associated with evening melatonin output in healthy controls (r
= 0.36), but not in premanifest HD individuals (Fig. 1F and Table 3).
This group diﬀerence in the correlation between hypothalamic volume
and evening melatonin output was statistically signiﬁcant (Fig. 1D,
Fig. 1F and Table 3). The group by melatonin output interaction encompassed the region extending from the superior tuberal hypothalamus to the anterior-inferior hypothalamus.
3.8. Associations between hypothalamic volume and habitual sleep
outcomes
No reliable pattern of associations was observed between hypothalamic volume and measures of subjective sleep quality, sleep onset latency, number of awakenings, sleep eﬃciency or perceived stress in the
premanifest HD or healthy cohorts.
4. Discussion
Hypothalamic pathology and disturbances in circadian rhythm and
sleep arise during the premanifest stages of HD. Despite the central role
of the hypothalamus in mediating the circadian rhythm and sleep-wake
timing, only one study has attempted to discern the possible relationship between hypothalamic pathology and sleep disturbances in individuals with HD (Baker et al., 2016). In the absence of robust data,
the aim of this study was to examine the potential relationship between
hypothalamic pathology and circadian rhythm and habitual sleep outcomes in individuals with premanifest HD.
Consistent with previous ﬁndings (Soneson et al., 2010), signiﬁcantly reduced grey matter volume was observed in the hypothalamus of individuals with premanifest HD compared to healthy controls. Using normative parcellations of the hypothalamus that rely on
6

Neurobiology of Sleep and Circadian Rhythms 6 (2019) 1–8

D.M. Bartlett et al.

Timothy Rankin, Dr Catarina Kordsachia and Professor Brian Power.

Despite observing diﬀerences in the relationships between hypothalamic grey matter volume and cortisol and melatonin in the premanifest HD cohort compared to healthy controls, no diﬀerences in
morning cortisol or evening melatonin release were observed between
the two groups, which is contradictory to previous reports (Kalliolia
et al., 2014; van Duijn et al., 2010). It is important to note that a large
proportion of our premanifest HD cohort were females (65.6%). This is
of relevance as sex-speciﬁc diﬀerences in circadian rhythm dysfunction
have been reported in HD mouse models (Kuljis et al., 2016). In particular, female HD mice exhibit less severe or delayed changes in activity levels and behavioural fragmentation compared to male HD mice
(Kuljis et al., 2016). Therefore, the lack of diﬀerences in cortisol and
melatonin release between individuals with premanifest HD and
healthy controls may be related to sex-speciﬁc eﬀects.
Conceivably, the right side of the hypothalamus, or indeed other
structures involved in the release of cortisol and melatonin, such as the
pituitary or pineal glands, may be able to compensate for the reduced
hypothalamic volume during the premanifest stages of the disease and
thereby maintain normal regulation of cortisol and melatonin release.
This is supported by emerging evidence indicating the presence of
compensatory neural functions in individuals with HD (Gregory et al.,
2017; Scheller et al., 2014). This theory nevertheless requires further
validation in larger longitudinal studies.
This study is not without limitations. Firstly, current imaging
methods are not yet sensitive enough to capture the individual nuclei
within the hypothalamus; however, parcellation approaches that rely
on anatomic landmarks visible on MR images (e.g. Makris et al., 2013)
allow the distinction of the diﬀerent hypothalamic regions, which affords some insight into which structures may be aﬀected. Secondly, this
study evaluated cortisol and melatonin regulation using saliva sampling, which is known to be more variable than blood sampling.
However, salivary cortisol and melatonin sampling was preferred to
blood sampling as previous studies indicate that blood sampling elevates cortisol levels (Weckesser et al., 2014). Thirdly, this study included a large proportion of females with HD, which may have inﬂuenced our ability to ﬁnd signiﬁcant diﬀerences in cortisol/melatonin
release between individuals with premanifest HD and healthy controls.
Discrepancies in cortisol and melatonin ﬁndings between this study and
others may also reﬂect diﬀerences in measurement protocols (i.e., frequency of sampling time points), patient characteristics or seasonal
diﬀerences (Kalliolia et al., 2014; Stothard et al., 2017; van Duijn et al.,
2010). A lack of concordance also existed between the habitual sleep
measures, potentially due to diﬀerences in reporting methods (i.e.
subjective versus objective). No evidence of elevated stress, anxiety or
depression was noted, indicating that mood disorders did not impact on
markers of circadian rhythm or habitual sleep. Future studies should
assess the relationship between hypothalamic pathology and sleep architecture in individuals with premanifest HD using polysomnography.
In summary, our ﬁndings show that individuals with premanifest
HD exhibit leftward biased hypothalamic pathology that is diﬀerentially associated with markers of circadian rhythm, but not consistently
associated with habitual sleep-wake deﬁcits, when compared to healthy
controls. However, the lack of diﬀerences in concentrations of markers
of circadian rhythm between the two groups suggests the possibility of
neural compensation, facilitated by the right hemisphere of the hypothalamus or by other brain structures involved in the circadian and
sleep cycles, as a mechanism involved in maintaining the regulation of
the circadian rhythm and habitual sleep-wake function in individuals
with premanifest HD. Larger, longitudinal studies are required to further investigate the role of hypothalamic pathology in circadian rhythm
and habitual sleep-wake disturbances in HD as the disease course
lengthens.
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